The main objective of this paper is to simplify the implementation of continuous and discontinuous 3-D space vector pulsewidth modulations (SVPWMs). This paper analyzes the relationships, whether in ...

In potential good news for Prothena, Roche announced earlier this week that it will advance Prothena-partnered prasinezumab into phase 3 trials for early-stage Parkinson’s disease, despite the ...

June 18, 2025 — 07:42 am EDT Written by None for Quiver Quantitative -> Biogen launches Phase 3 BRAVE study to assess omaveloxolone's effects in children with Friedreich ataxia. Quiver AI Summary ...

The Soo Locks SAULT STE. MARIE, Mich. — U.S. Army Corps of Engineers, Detroit District’s New Lock at the Soo project in Sault Ste. Marie, Michigan, awards a total of $95.3 million for remaining Phase ...

PETACH TIKVA, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (" PolyPid ” or the " Company ”), a late-stage biopharma company aiming to improve surgical outcomes, today ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to begin a phase 2/3 pivotal confirmatory trial of OCU410ST. OCU410ST uses an ...

This paper presents a new high-order filter for three-phase grid-connected voltage source converters (VSCs) named the inductor-trap-capacitor-inductor (LTCL) filter, in which multiple LC trap filters ...

Luis Diaz has been linked with a summer move to Barcelona Meanwhile, Saudi Arabian side Al-Nassr has identified Diaz as its “top summer transfer target,” a ccording to talkSPORT Click to visit ...

Although not statistically significant, in a phase 2b study, the influenza symptom remission time in patients receiving pimodivir (VX-787) showed a tendency to be faster than that of the placebo group ...

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.

In the Phase 3 VISIONARY study, sibeprenlimab achieved a statistically significant and clinically meaningful 51.2% (P<0.0001) reduction in proteinuria at nine months of treatment when compared to ...